The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: A case control study

Hereditary Cancer in Clinical Practice

Volumn 11, Issue 1, 2013, Pages

  Jones, Dominique Z ^a   Ragin, Camille ^b   Kidd, Nayla C ^a   Flores Obando, Rafael E ^c   Jackson, Maria ^d   McFarlane Anderson, Norma ^d   Tulloch Reid, Marshall ^e   Kimbro, Kevin S ^f   Kidd, LaCreis R ^a  

^a University of Louisville School of Medicine   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF THE WEST INDIES   (Jamaica)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

Inflammatory related sequence variants; Prostate cancer; Single nucleotide polymorphisms

Indexed keywords

EID: 84890743695     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-11-19     Document Type: Article

References (30)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867. 10.1038/nature01322, 2803035, 12490959.
2. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C. Inflammation and prostate cancer. Future Oncol 2008, 4(5):637-645. 10.2217/14796694.4.5.637, 18922121.
3. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology 2012, 60(1):199-215. 10.1111/j.1365-2559.2011.04033.x, 22212087.
4. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013, 49(4):938-945. 10.1016/j.ejca.2012.09.030, 23079475.
5. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci 1997, 2:d12-d26.
6. Dluzniewski PJ, Wang MH, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD, Xu J, et al. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2012, 21(10):1774-1782. 10.1158/1055-9965.EPI-12-0458, 3467312, 22859398.
7. Berhane N, Sobti RC, Melesse S, Mahdi SA, Kassu A. Significance of Tumor necrosis factor alpha-308 (G/A) gene polymorphism in the development of prostate cancer. Mol Biol Rep 2012, 39(12):11125-11130. 10.1007/s11033-012-2020-2, 23065208.
8. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev 2011, 20(9):1928-1936. 10.1158/1055-9965.EPI-11-0236, 3169727, 21846818.
9. Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, Alvarez JC, Lorente JA, Cozar JM. RNASEL study of genetics of prostate cancer and its relation to clinical staging. Actas Urol Esp 2012, 36(5):306-311.
10. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002, 32(4):581-583. 10.1038/ng1021, 12415269.
11. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN, Mittal RD. IL-10-1082 G > A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009, 27(3):389-396. 10.1007/s00345-008-0361-1, 19145440.
12. Tindall EA, Severi G, Hoang HN, Southey MC, English DR, Hopper JL, Giles GG, Hayes VM. Interleukin-6 promoter variants, prostate cancer risk, and survival. Prostate 2012, 72(16):1701-1707. 10.1002/pros.22557, 22782910.
13. Tindall EA, Severi G, Hoang HN, Ma CS, Fernandez P, Southey MC, English DR, Hopper JL, Heyns CF, Tangye SG, et al. Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk. Carcinogenesis 2010, 31(10):1748-1754. 10.1093/carcin/bgq081, 20403914.
14. American Cancer S Cancer Facts and Figures 2012 2012, American Cancer Society: Atlanta, Georgia, American Cancer S.
15. American Cancer S Cancer Facts & Figures for African Americans 2011-2012 2011, American Cancer Society: Atlanta, American Cancer S.
16. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008, 29(3):573-578.
17. Zabaleta J, Su LJ, Lin HY, Sierra RA, Hall MC, Sartor AO, Clark PE, Hu JJ, Ochoa AC. Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis 2009, 30(8):1358-1362. 10.1093/carcin/bgp124, 2718072, 19474090.
18. Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, Ragin C, Jackson M, McFarlane-Anderson N, Tulloch-Reid M, et al. Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hereditary Cancer Clin Prac 2012, 10(1):16.
19. Jackson MD, Walker SP, Simpson-Smith CM, Lindsay CM, Smith G, McFarlane-Anderson N, Bennett FI, Coard KC, Aiken WD, Tulloch T, et al. Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control 2012, 23(1):23-33. 10.1007/s10552-011-9850-4, 21984307.
20. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753. 10.1038/nature08494, 2831613, 19812666.
21. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9(5):356-369. 10.1038/nrg2344, 18398418.
22. Steemers FJ, Gunderson KL. Whole genome genotyping technologies on the Bead Array platform. Biotechnol J 2007, 2(1):41-49. 10.1002/biot.200600213, 17225249.
23. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008, 9:36. 2387159, 18477402.
24. Song N, Han S, Lee KM, Choi JY, Park SK, Jeon S, Lee Y, Ahn HS, Shin HY, Kang HJ, et al. Genetic variants in interleukin-2 and risk of lymphoma among children in Korea. Asian Pac J Cancer Prev 2012, 13(2):621-623. 10.7314/APJCP.2012.13.2.621, 22524835.
25. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002, 100(3):249-260. 10.1002/ijc.10466, 12115538.
26. Lin HC, Liu CC, Kang WY, Yu CC, Wu TT, Wang JS, Wu WJ, Huang CH, Wu MT, Huang SP. Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol Int 2009, 83(4):463-470. 10.1159/000251189, 19996656.
27. Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One 2011, 6(7):e21650. 10.1371/journal.pone.0021650, 3128608, 21747944.
28. Chang SY, Su PF, Lee TC. Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1alpha pathway. Cytokine 2009, 45(1):32-38. 10.1016/j.cyto.2008.10.013, 19026558.
29. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004, 100(7):1388-1396. 10.1002/cncr.20142, 15042672.
30. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009, 41(5):524-526. 10.1038/ng.371, 2898503, 19396167.